title: Testicular cancer in blacks. A multicenter experience.
abstract: BACKGROUND
  The rarity of testis tumor in black patients has made the study of a large series difficult. Much of the epidemiologic and clinical information regarding this neoplasm in this population is in dispute, including data on incidence, prognosis, histologic distribution, age and stage at presentation, and side distribution.
  
  
  METHODS
  A retrospective review of 66 blacks with testicular tumors from seven military medical centers was performed.
  
  
  RESULTS
  Similar results were found for blacks with testis tumor to those of the general testis cancer population regarding prognosis, side distribution, and age of onset for nonseminoma and interstitial tumors. There is a slight increase in the expected number of interstitial tumors in blacks, but the distribution between seminoma and nonseminoma is similar to the general population. The mean age of presentation for seminoma in blacks was younger than that of the general testis cancer population. For testis tumor treated at the same institution, there was an increased delay of diagnosis in blacks compared with whites. The number of new cases of testicular cancer between 1979 and 1991 at one major center was increased for whites but not for blacks. The availability of cisplatin-based combination chemotherapy has resulted in an improved prognosis for blacks, as has already been demonstrated for white populations.
  
  
  CONCLUSIONS
  Testis tumor in blacks behaves similarly to testis tumor in the general population except that in blacks there are more interstitial tumors and the mean age of presentation for seminoma is younger. Further, there is an increased delay in diagnosis for blacks compared with whites, but the incidence of this tumor in this population does not appear to be increasing. Cisplatin-based chemotherapy has significantly improved survival in this population.
authors.affiliation: Urology Services, Walter Reed Army Medical Center, Washington, DC.
authors.forename: J W
authors.initials: JW
authors.lastname: Moul
authors.forename: F J
authors.initials: FJ
authors.lastname: Schanne
authors.forename: I M
authors.initials: IM
authors.lastname: Thompson
authors.forename: H A
authors.initials: HA
authors.lastname: Frazier
authors.forename: S A
authors.initials: SA
authors.lastname: Peretsman
authors.forename: J N
authors.initials: JN
authors.lastname: Wettlaufer
authors.forename: T A
authors.initials: TA
authors.lastname: Rozanski
authors.forename: R S
authors.initials: RS
authors.lastname: Stack
authors.forename: K J
authors.initials: KJ
authors.lastname: Kreder
authors.forename: K J
authors.initials: KJ
authors.lastname: Hoffman
mesh_terms: D000328:Adult; D000367:Age Factors; D044383:Black People; D002945:Cisplatin / Q000627:therapeutic use; D006801:Humans; D007984:Leydig Cell Tumor / Q000453:epidemiology; D008297:Male; D011379:Prognosis; D018239:Seminoma / Q000453:epidemiology; D012707:Sertoli Cell Tumor / Q000453:epidemiology; D013736:Testicular Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology*; D014481:United States / Q000453:epidemiology; D001741:Black or African American
chemical_list: D002945:Cisplatin